Data/Analytics

Five big shifts in policy and technology that marketers should worry about in 2015

Five big shifts in policy and technology that marketers should worry about in 2015

"The trouble is that the market is changing much faster than most marketers realize."

Millennials don't care about traditional healthcare: study

Millennials don't care about traditional healthcare: study

Members of the 13-32 age group were less likely to agree that preventive care is the most important factor in staying healthy, compared to Baby Boomers and Gen-Xers.

Point-of-care messaging growth surpasses DTC growth: study

Point-of-care messaging growth surpasses DTC growth: study

As patients spend more time in waiting rooms where they are primed to learn about their health, POC promotions are becoming a more essential part of the marketing mix, researchers find.

Sharecare scales up again with QualityHealth buy

Sharecare scales up again with QualityHealth buy

Complementary solutions to drive growth with health plans as well as pharma clients, companies say.

Health systems are embracing value-based care: survey

Health systems are embracing value-based care: survey

Despite hurdles of practitioner buy-in and legacy IT, value-based care is on pace to overtake fee-for-service.

Demand for Harvoni limited by insurance reimbursement: KOLs

An arduous reimbursement process has put a damper on how quickly patients can receive the drug, say analysts, citing KOLs.

Five things for pharma marketers to know: Tuesday, November 12

Five things for pharma marketers to know: Tuesday, November 12

Life expectancy for patients cured of advanced HCV similar to healthy peers: study; Ackman takes a $2 billion stake in animal drugmaker Zoetis; Amgen and AstraZeneca report that brodalumab bested Stelara in psoriasis head-to-head.

HHS dials back ACA enrollment forecast

The CBO projected 13 million enrolled in 2015, but its projections were based before final 2014 numbers were in.

Five things for pharma marketers to know: Tuesday, November 11

Five things for pharma marketers to know: Tuesday, November 11

FDA will evaluate effect of pharma commercial barrage; Pfizer settles Neurontin marketing lawsuit for $321 million; AbbVie and Gilead release top-line results on HCV combo therapies.

Finding value in generic drugs with a twist

Finding value in generic drugs with a twist

Developing exclusive features from proven generics is a growing opportunity for patients as much as it is a ploy for life-cycle extension.


Does a health psychology approach hold the key to Rx adherence? In MM&M's latest Leadership Exchange Uncut eBook, industry stakeholders from the payer, provider, academic and pharma realms explore the "why" behind medicine taking. Access here.